EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Nabilone treatment for severe behavioral problems in adults with intellectual and developmental disabilities: Protocol for a phase I open-label clinical trial

Hsiang-Yuan Lin iD, Elia Abi-Jaoude, Pushpal Desarkar, Wei Wang, Stephanie H Ameis, Meng-Chuan Lai iD, Yona Lunsky iD, Tarek K Rajji iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0282114 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2023. Verfasst von Hsiang-Yuan Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Azrieli Adult Neurodevelopmental Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, …. Hauptthemen laut MEDLINE: Cannabinoids, Intellectual Disability, Problem Behavior. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Psychiatry, University of Toronto, CAMH Academic Health Science Centre Alternative Funding Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe behavioral problems (SBPs) are common contributors to morbidity and reduced quality of life for adults with intellectual and developmental disabilities (IDD) and their families. Current medications for SBPs show equivocal effectiveness and are associated with a high risk of side effects. New and safe treatments are urgently needed. While preliminary studies suggest that medical cannabinoids, particularly the synthetic cannabinoid nabilone, are plausible treatment options for SBPs in adults with IDD, data on the tolerability, safety and efficacy of nabilone in this population has never been investigated. Thus, we propose this first-ever Phase I pre-pilot open-label clinical trial to obtain preliminary data on the adherence, tolerability and safety profiles of nabilone in adults with IDD, and explore changes in SBPs pre- to post-treatment. We hypothesize that nabilone has favorable tolerability and safety profile for adults with IDD. The preliminary results will inform the next-stage pilot randomized controlled trials, followed by fully powered clinical trials eventually. This research helps fill the evidence gap in the use of cannabinoids in individuals with IDD to meet the needs of patients, families, and service providers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsIntellectual DisabilityProblem BehaviorAdultChildHumansDevelopmental DisabilitiesQuality of LifeClinical Trials, Phase I as TopicDronabinol

Substanzen

CannabinoidsnabiloneDronabinol

Autor:innen und Institutionen

  • Azrieli Adult Neurodevelopmental Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Adult Neurodevelopment and Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Canada.
  • Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Department of Psychiatry, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
  • Centre for Complex Interventions, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

ORCID-Profile: Hsiang-Yuan Lin, Meng-Chuan Lai, Yona Lunsky, Tarek K Rajji

Förderung

  • Department of Psychiatry, University of Toronto
  • CAMH Academic Health Science Centre Alternative Funding Plan

Zitieren

APA

Lin, H. Y., Abi-Jaoude, E., Desarkar, P., Wang, W., Ameis, S. H., Lai, M. C., Lunsky, Y., & Rajji, T. K. (2023). Nabilone treatment for severe behavioral problems in adults with intellectual and developmental disabilities: Protocol for a phase I open-label clinical trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0282114

Vancouver

Lin HY, Abi-Jaoude E, Desarkar P, Wang W, Ameis SH, Lai MC, et al. Nabilone treatment for severe behavioral problems in adults with intellectual and developmental disabilities: Protocol for a phase I open-label clinical trial. PLOS ONE. 2023. doi:10.1371/journal.pone.0282114

BibTeX
@article{Lin2023,
  author = {Lin, Hsiang-Yuan and Abi-Jaoude, Elia and Desarkar, Pushpal and Wang, Wei and Ameis, Stephanie H and Lai, Meng-Chuan and Lunsky, Yona and Rajji, Tarek K},
  title = {Nabilone treatment for severe behavioral problems in adults with intellectual and developmental disabilities: Protocol for a phase I open-label clinical trial},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0282114}
}
Kostenlos starten →